LONG-ACTING PROPRANOLOL IN THE PROPHYLAXIS OF MIGRAINE - A COMPARATIVE-STUDY OF 2 DOSES

被引：17

作者：

CARROLL, JD

REIDY, M

SAVUNDRA, PA

CLEAVE, N

MCAINSH, J

机构：

[1] Regional Neurological Unit, Royal Surrey County Hospital, Guildford, Surrey, UK

[2] Centre of Mathematical Software Research, University of Liverpool, Liverpool, UK

[3] ICI Pharmaceuticals, Macclesfield, Cheshire, UK, Mereside, Alderley Park

来源：

CEPHALALGIA | 1990年 / 10卷 / 02期

关键词：

D O I：

10.1046/j.1468-2982.1990.1002101.x

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

A randomized double-blind, cross-over study using treatment periods of 12 weeks with a 2-week washout, comparing two long-acting formulations of propranolol (‘Inderal’*(1 LA 160 mg daily and Half-‘Inderal’ LA 80 mg daily) was performed after a placebo run-in of 4 weeks on 51 patients. The study indicated that both long-acting formulations were significantly better than placebo in reducing the frequency of migraine attacks (p < 0.01). After 12 weeks there was a significantly lower (p = 0.03) frequency of migraine attacks in patients on the higher dose formulation than in those on the lower dose formulation. There was no significant difference in the frequency of side effects produced by the two formulations. © 1990, International Headache Society. All rights reserved.

引用

页码：101 / 105

页数：5

共 29 条

[1]

Diamond S., Kudrow L., Stevens J., Shapiro D.B., Long-term study of propranolol in the treatment of migraine, Headache, 22, 6, pp. 268-271, (1982)

[2]

McAinsh J., Rowe R.C., Sustained release pharmaceutical composition, United States Patent 4, (1979)

[3]

McAinsh J., Barber N.S., Smith R., Young J., Pharmacokinetic and pharmacodynamic studies with long acting propranolol, Br J Clin Pharmacol, 6, pp. 115-121, (1978)

[4]

Leahey W.J., Neill J.D., Varma M.P.S., Shanks R.G., Comparison of the efficacy and pharmacokinetics of conventional propranolol and a long acting preparation of propranolol, Br J Clin Pharmacol, 9, pp. 33-40, (1980)

[5]

McAinsh J., Baber N.S., Holmes B.F., Young J., Ellis S.H., Bioavailability of sustained release propranolol formulations, Biopharm Drug Disp, 2, pp. 39-48, (1981)

[6]

Drummer O.H., McNeil J., Pritchard E., Louis W.J., Combined high-performance liquid chromatographic procedure for measuring 4-hydroxy-propranolol and propranolol in plasma. Pharmacokinetic measurements following conventional and slow-release propranolol administration, J Pharm Sci, 70, pp. 1030-1032, (1981)

[7]

Serlin M.J., Orme M.L., Maclver M., Green G.J., Sibeon R.G., Breckenridge A.M., The pharmacodynamics and pharmacokinetics of conventional and long-acting propranolol in patients with moderate hypertension, Br J Clin Pharmacol, 15, pp. 519-527, (1983)

[8]

Ohashi K., Ebihara A., Kondo K., Usami M., Clinical pharmacokinetics and pharmacological actions of a long-acting formulation of propranolol, Arzneim Forsch, 34, pp. 507-512, (1984)

[9]

Ziam B., Kraml M., Dvornik D., Ryder G., Mullane J.F., ‘Inderal’ LA: comparison of the profiles of plasma drug concentration/time curves produced in man by propranolol hydrochloride long-acting (80 and 60 mg) and atenolol (50 and 100 mg, Curr Ther Res, 5, pp. 896-904, (1984)

[10]

Ravenscroft P.J., Charles B.G., Renshaw P.J., The bioavailability of propranolol and 4-hydroxy-propranolol: a comparison of conventional and long-acting preparations, Aust Soc Clin Exp Pharmacol, (1981)

← 1 2 3 →